BRAF and neoplasm: In addition, quantitative analysis of tumor growth and metabolomic data by NMR-metabolomics showed that the combination of everolimus and irinotecan was more beneficial in BRAF/PIK3CA-mutant HT29 tumor xenografts, where it had an additive effect, than in KRAS/PIK3CA-mutant HCT116 tumor xenografts, where it had a less additive effect [6].